A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
03/2011
03/23/2011	EP2298810A2 Treatment of TNF alpha related disorders
03/23/2011	EP2298761A1 HIV inhibiting pyrimidines derivatives
03/23/2011	EP2298281A1 Infusion and injection solution of Levodopa
03/23/2011	EP1448205B1 Combinations for the treatment of immunoinflammatory disorders
03/22/2011	US7910589 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
03/22/2011	US7910544 Conformationally constrained parthyroid hormone (PTH) analogs
03/22/2011	US7910523 Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
03/22/2011	US7910111 Inhibitors of N-ethylmaleimide sensitive factor
03/22/2011	US7910093 administering to mammals a Sindbis virus comprising gene that code detectable labels, concurrently with anticarcinogenic agents, and analyzing the amount of cancer cells in the body of the mammal
03/22/2011	CA2525970C Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis
03/22/2011	CA2513102C Substituted pyrazoles, compositions containing such compounds and methods of use
03/22/2011	CA2442960C Vessel sealing instrument
03/17/2011	US20110065090 Asymmetrically branched polymer conjugates and microarray assays
03/17/2011	US20110064729 Administration of agents for the treatment of inflammation
03/16/2011	EP2295464A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295463A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295462A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295461A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295460A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295459A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295458A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295457A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/16/2011	EP2295415A1 Quinazoline derivatives
03/16/2011	EP2295071A1 Low dose methods for treating disorders in which TNF-alpha activity is detrimental
03/16/2011	EP1326633B1 Composition comprising immunogenic microparticles
03/16/2011	CN101985443A Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
03/15/2011	US7906531 M3 muscarinic acetylcholine receptor antagonists
03/15/2011	US7906520 Reducing expression of tetrahydrobiopterin (BH4) biological activity; traumatic, metabolic or toxic peripheral nerve lesions
03/15/2011	CA2528385C A1 adenosine receptor antogonists
03/15/2011	CA2432000C Pyrimidineamines as angiogenesis modulators
03/15/2011	CA2426921C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
03/15/2011	CA2394535C Hair bleaching and colouring compositions having a ph greater than ph 10 comprising cholesterol
03/09/2011	EP2292634A2 Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
03/09/2011	EP1575548B1 Compositions and methods for promoting neuronal outgrowth
03/09/2011	CN1582274B Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
03/09/2011	CN101297969B Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications
03/08/2011	US7902360 e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility
03/08/2011	US7901681 Trypanosome derived apoptotic factors (TAF)
03/08/2011	US7901671 Therapeutic retroviral vectors for gene therapy
03/08/2011	CA2689051C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
03/03/2011	US20110055937 Keratin 8 Mutations are Risk Factors for Developing Liver Disease of Multiple Etiologies
03/03/2011	US20110054160 Therapeutic compositions
03/03/2011	US20110053243 Asymmetrically branched polymer conjugates and microarray assays
03/03/2011	US20110053182 Diagnosis of pre-cancerous conditions using pcdgf agents
03/03/2011	US20110053175 Asymmetrically branched polymer conjugates and microarray assays
03/03/2011	US20110052733 Herbal compositions for the treatment of mucosal lesions
03/03/2011	US20110052528 Neuroprotective macrocyclic compounds and methods for their use
03/02/2011	EP2290104A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
03/02/2011	EP2290103A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
03/02/2011	EP2290079A2 Neurotrophic factors
03/02/2011	EP2289941A2 Administration of agents for the treatment of inflammation
03/02/2011	EP2289936A1 Immunoglobulin variants and uses thereof
03/02/2011	EP2289935A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289934A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289933A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289932A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289931A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289930A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289929A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289928A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289927A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289926A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289925A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289924A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289923A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289922A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289921A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289920A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289919A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289918A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289917A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289916A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289915A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289914A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289913A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289912A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
03/02/2011	EP2289876A1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer
03/02/2011	EP2289559A1 Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
03/02/2011	EP2289548A2 Combined vaccines comprising hepatitis B surface antigen and other antigens
03/02/2011	EP2289521A2 Compositions and methods for use in tergeting vascular destruction
03/02/2011	EP2289517A2 Controlled release oxycodone compositions
03/02/2011	EP1423101B1 Use of a plaster for the treatment of onychomycoses
03/02/2011	EP1001945B1 QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES
03/02/2011	CN1674935B Biofunctional composition containing CpG or oligo-/polynucleotide and toxin or enterotoxin
03/01/2011	USRE42191 Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
03/01/2011	US7897767 Oxime substituted imidazoquinolines
03/01/2011	US7897590 Methods to mobilize progenitor/stem cells
03/01/2011	US7897158 Recombinant toxin fragments
03/01/2011	CA2348954C A pharmaceutical composition for treating immune diseases
02/2011
02/24/2011	US20110046103 Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-Containing Compositions
02/23/2011	EP2287337A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
02/23/2011	EP2287192A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
02/23/2011	EP2287168A2 Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
02/23/2011	EP2286818A1 Fulvestrant formulation
02/23/2011	EP2286817A2 Method of treating functional bowel disorders
02/23/2011	EP2286811A1 Chemokine receptor antagonists and methods of use thereof
02/23/2011	CN101980017A Anti-TNF antibodies, compositions, methods and uses
02/22/2011	US7893217 Isolated human antibodies that bind epitopes on RG1
02/22/2011	US7893215 Agonist antibodies to IL-23 receptor
02/22/2011	US7893109 N,N-dihalogenated amino acids and derivatives

1 ... 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ... 295